Skip to main content
MedPathMedPath Home
Clinical Trials/2022-502881-25-00
2022-502881-25-00
Completed
Phase 2

A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors (PRESent-3)

Apcintex Limited6 sites in 4 countries6 target enrollmentStarted: August 7, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Status
Completed
Sponsor
Apcintex Limited
Enrollment
6
Locations
6
Primary Endpoint
Study Endpoint: Treated bleeds (expressed as annualized bleeding rate [ABR]) in the observation period and during the first 24 weeks under SerpinPC
OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

To evaluate the efficacy and safety of prophylactic SerpinPC administered subcutaneously in subjects with hemophilia B (HemB) with inhibitors

Study Design

Allocation
Not Applicable
Primary Purpose
Open-label
Masking
None

Eligibility Criteria

Ages
0 years to 64 years (18-64 Years, 0-17 Years)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Male subjects ≥12 and ≤65 years of age at the time of informed consent
  • •Adequate hematologic function, defined as a platelet count of ≥100,000/μL (≥100 × 109/L) and hemoglobin level of ≥10 g/dL (≥100 g/L or ≥ 6.206 mmol/L) at Screening and Pre-dosing visits
  • •Adequate hepatic function, defined as a total bilirubin level of ≤1.5 × upper level of normal (ULN, excluding Gilbert syndrome) and aspartate aminotransferase and/or alanine aminotransferase of ≤3 × ULN at Screening and Pre-dosing visits; no clinical signs or known laboratory or radiographic evidence consistent with cirrhosis of the liver
  • •Adequate renal function, defined as a serum creatinine level of ≤2.0 × ULN at Screening and Pre-dosing visits
  • •Able to use a diary to document bleeding events and medication usage (caregiver assistance allowed for adolescents)
  • •Sexually active subjects with a partner who could become pregnant should agree to use effective contraception for the duration of the study Effective contraceptive measures include condom with or without spermicide, a combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods), vasectomy, partner using stable contraceptive measures (combined [estrogen and progestogen-containing] hormonal contraception or progestogen-only hormonal contraception initiated 2 or more menstrual cycles prior to screening, intrauterine device [IUD], intrauterine hormone-releasing system [IUS], bilateral tubal ligation), and/or sexual abstinence
  • •Capable of providing written informed consent (adolescent assent and parental/guardian/legal representative consent when appropriate) for participation and having the opportunity to discuss the study with the Investigator or delegate
  • •Historically documented HemB (defined as factor IX ≤0.05 IU/mL [≤5%])
  • •Subjects who are currently in a prophylaxis program must be willing to stop prophylaxis (including episodic prophylaxis for sporting events) before the first dose of SerpinPC
  • •Historical or ongoing factor IX inhibitor requiring current treatment with bypass agents based on medical records or laboratory reports

Exclusion Criteria

  • •Known severe thrombophilia (defined as antithrombin deficiency and/or protein S deficiency and/or protein C deficiency)
  • •Any major medical, psychological, or psychiatric condition that could cause the subject to be unsuitable for the study or could interfere with the interpretation of the study results
  • •History of or other evidence of recent alcohol or drug abuse as determined by the Investigator (in the 12 months before screening)
  • •Known HIV infection with CD4 count (or T-cell count) of <200 cells/μL within 24 weeks before Screening and Pre-dosing visits. Patients with HIV infection who have CD4 > 200 and meet all other criteria are eligible
  • •Current or planned treatment with anticoagulant or antiplatelet drugs
  • •Is planning to donate/bank sperm during SerpinPC treatment AND within 30 days of last dose of SerpinPC
  • •Any other significant conditions or comorbidities that, in the opinion of the Investigator, would make the subject unsuitable for enrollment, or could interfere with participation in, or completion of the study
  • •Patient with previous factor IX inhibitor who responded to immune tolerance induction and remains on prophylactic factor concentrate
  • •Previous deep vein thrombosis (excluding line-associated thrombosis), pulmonary embolism, myocardial infarction, or stroke
  • •History of intolerance to SC injections

Outcomes

Primary Outcomes

Study Endpoint: Treated bleeds (expressed as annualized bleeding rate [ABR]) in the observation period and during the first 24 weeks under SerpinPC

Study Endpoint: Treated bleeds (expressed as annualized bleeding rate [ABR]) in the observation period and during the first 24 weeks under SerpinPC

Secondary Outcomes

  • • Treated bleeds (expressed as ABR) other than those defined by the primary endpoint (eg, during the first 48 weeks)
  • • Treated spontaneous bleeds (expressed as ABR)
  • • Treated spontaneous joint bleeds (expressed as ABR)
  • • All bleeds requiring treatment (expressed as ABR; ie, all bleeds that would ordinarily be treated with factor concentrate/bypass agent if therapy were available)
  • • Total coagulation factor and/or bypass product consumption during SerpinPC treatment
  • • PK concentrations of SerpinPC throughout the study
  • • Haemophilia Quality-of-Life Questionnaire for Adults (Haem-A-QoL) Physical Health scale in subjects aged 17 to ≤65 years

Investigators

Sponsor
Apcintex Limited
Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Chief Medical Officer

Scientific

Apcintex Limited

Study Sites (6)

Loading locations...

Similar Trials

Active, not recruiting
Phase 3
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
2024-512837-34-00Teva Branded Pharmaceutical Products R&D LLC249
Recruiting
Early Phase 1
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
NCT07275736Juventas Cell Therapy Ltd.18
Not yet recruiting
Not Applicable
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
NCT07265206Juventas Cell Therapy Ltd.15
Active, not recruiting
Phase 3
Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors
2023-506832-33-00Novo Nordisk A/S43
Not yet recruiting
Phase 1/2
A clinical study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SB-007 in Subjects with Stargardt Disease.
2024-519535-42-00Splicebio S.L.10